The leaders of Japan and China got off to a tense start but have made significant progress in turning around their relations in recent years.Asia Politicsread more
Tech's hottest IPOs of the year, including Beyond Meat and Zoom, dropped on Monday, falling more than the broader market.Technologyread more
"We do not seek conflict with Iran or any other country," Trump tells reporters in the Oval Office.Politicsread more
Stocks in Asia were tepid in Tuesday morning trade, while investors looked toward to a meeting between U.S. President Donald Trump and Chinese President Xi Jinping set to...Asia Marketsread more
Chinese Vice Premier Liu He held a phone conversation with U.S. Trade Representative Robert Lighthizer and U.S. Treasury Secretary Steven Mnuchin, China's Ministry of Commerce...World Economyread more
Sen. Bernie Sanders announced a plan Monday to forgive the country's $1.6 trillion outstanding student loan tab, intensifying the higher education policy debate in the 2020...Personal Financeread more
While earnings usually come in substantially ahead of expectations — as much as 4 or 5 percentage points is not unusual — the downward direction in the outlook doesn't speak...Earningsread more
U.S. President Donald Trump's senior adviser Kellyanne Conway will not testify before the House of Representatives Oversight Committee this week on her alleged violations of...Politicsread more
"We missed being the dominant mobile operating system by a very tiny amount. We were distracted during our antitrust trial. We didn't assign the best people to do the work,"...Technologyread more
PatientsLikeMe was bought by UnitedHealth following a review by Trump's Treasury Department, which scrutinized the start-up because it's backed by Chinese cash.Technologyread more
Some traders think the energy rally is about to wane, despite the sector being one of June's big winners.ETF Edgeread more
Shares of drugmakers Mylan, which was also named in the lawsuit, were trading 10% lower in afternoon trading.
The states, led Connecticut Attorney General William Tong, claim 20 drug companies, including Teva USA, "systematically" divided up the market for generic drugs to avoid competing with one another, according to a 500-page lawsuit filed late Friday in the U.S. District Court in Connecticut. In some cases, pharmaceutical executives conspired to either prevent prices from dropping or raise them, the lawsuit claimed.
"This is an organized effort to conspire and fix prices — a highly illegal violation of antitrust laws," Tong said.
The lawsuit comes as President Donald Trump and Congress attempt to bring down high prescription drug prices, which accounted for roughly 12% of total health-care spending in the U.S. in 2016. Just last week, the Trump administration announced it would required pharmaceutical companies to disclose the list price of their prescription medicines in television commercials in an effort to "shame" them into lowering consumer costs.
In response to the lawsuit, a spokesperson for Teva said "the allegations in this new complaint, and in the litigation more generally, are just that – allegations."
"Teva continues to review the issue internally and has not engaged in any conduct that would lead to civil or criminal liability," the spokesperson said. "Teva delivers high-quality medicines to patients around the world, and is committed to complying with all applicable laws and regulations in doing so."
The generic drug industry was created by Congress in 1984 in an effort to bring down drug prices by allowing companies to make their own identical version of a drug once a brand-name drug's patent expired.
Israel-based Teva is the world's largest generic drugmaker.
For more on investing in health-care innovation, click here to join CNBC at our Healthy Returns Summit in New York City on May 21.